# Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

> **NCT04010968** · PHASE2 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 120 (actual)

## Conditions studied

- Intermediate Risk Chronic Lymphocytic Leukemia
- Fit Patients
- Risk-Adapted and MRD-Driven Strategy

## Interventions

- **DRUG:** venetoclax and ibrutinib (I+VEN)
- **DRUG:** FCR

## Key facts

- **NCT ID:** NCT04010968
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-27
- **Primary completion:** 2023-04-03
- **Final completion:** 2025-01-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04010968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04010968, "Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04010968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*